Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey S Humphrey

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
GCP data quality for early clinical developmentEdwin P Rock, Vernette J Molloy, Jeffrey S Humphrey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancerNaiyer A Rizvi, Jeffrey S Humphrey, Elizabeth A Ness, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
The Journal of Clinical Endocrinology and Metabolism|April 29, 2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23Erik A Imel, Xiaoping Zhang, Mary D Ruppe, et al.
Bone Reports|March 23, 2017
Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemiaMary D Ruppe, Xiaoping Zhang, Erik A Imel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitorA Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18Natasha B Leighl, Luis Paz-Ares, Jean-Yves Douillard, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
GCP data quality for early clinical developmentEdwin P Rock, Vernette J Molloy, Jeffrey S Humphrey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancerNaiyer A Rizvi, Jeffrey S Humphrey, Elizabeth A Ness, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
The Journal of Clinical Endocrinology and Metabolism|April 29, 2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23Erik A Imel, Xiaoping Zhang, Mary D Ruppe, et al.
Bone Reports|March 23, 2017
Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemiaMary D Ruppe, Xiaoping Zhang, Erik A Imel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitorA Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18Natasha B Leighl, Luis Paz-Ares, Jean-Yves Douillard, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Pageof 1